The further improvement of therapeutic strategies expected in the next future will likely increase the survival of patients with HER2-positive early breast cancer, thus requiring the current version of PREDICT to be updated to provide reliable prognostic estimation in these patients. This evidence concerns the gene ERBB2 and breast carcinoma.